Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT).

[1]  Ke Sheng,et al.  Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[2]  A. Bezjak,et al.  Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Tarek Mekhail,et al.  A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Jan Nyman,et al.  Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  T. Nagaoka,et al.  Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions. , 2009, International journal of radiation oncology, biology, physics.

[6]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[7]  Kenneth E Rosenzweig,et al.  Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? , 2008, International journal of radiation oncology, biology, physics.

[8]  S. Tung,et al.  Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer--report on clinical outcome and dose to critical organs. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Lech Papiez,et al.  Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[10]  E. Smit,et al.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[11]  Frederik Wenz,et al.  Predictive factors for late normal tissue complications following radiotherapy for breast cancer , 2007, Breast Cancer Research and Treatment.

[12]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Goodwin,et al.  Late gastrointestinal toxicity after radiation for prostate cancer , 2006, Cancer.

[14]  J. Beitler,et al.  Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. , 2006, International journal of radiation oncology, biology, physics.

[15]  Jan Nyman,et al.  Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries , 2006, Acta oncologica.

[16]  Abraham Philip,et al.  Stereotactic Body Radiation Therapy (SBRT) for lung metastases , 2006, Acta oncologica.

[17]  Masahiro Hiraoka,et al.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.

[18]  Kurt Baier,et al.  Dose-response in stereotactic irradiation of lung tumors. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  A. Ho,et al.  Postthoracotomy pain syndrome. , 2004, Thoracic surgery clinics.

[20]  Stephanie Frost,et al.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.

[21]  Shinichi Shimizu,et al.  Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. , 2003, International journal of radiation oncology, biology, physics.

[22]  J. Wong,et al.  Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. , 2001, International journal of radiation oncology, biology, physics.

[23]  L. Gaspar,et al.  Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. , 2009, International journal of radiation oncology, biology, physics.

[24]  Hiroki Shirato,et al.  STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .

[25]  K. Johansson,et al.  Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. , 2006, Lung cancer.